JGC
ANAC

J. Goldman & Co’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

J. Goldman & Co’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-52,000
Closed -$5.87M – 411
2015
Q4 		$5.87M Buy
+52,000
New +$5.73M 0.61% 57

Other funds holding ANAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

J. Goldman & Co's ANAC Position: Q1 2016 in Review

J. Goldman & Co sold out of ANACOR PHARMACEUTICALS INC COM (ANAC) in Q1 2016, closing a stake of 940 shares — an estimated $106K sold.

J. Goldman & Co first reported a position in ANAC in Q3 2013 and held it in 4 quarters. The position peaked at $4.02M in Q3 2015. 199 funds tracked by Wall St. Rank hold ANAC as of Q1 2016.

  • J. Goldman & Co reported no remaining ANACOR PHARMACEUTICALS INC COM position as of Q1 2016 after selling out during the quarter.
  • J. Goldman & Co sold 940 ANACOR PHARMACEUTICALS INC COM shares in Q1 2016, an estimated $106K.
  • J. Goldman & Co first reported a position in ANACOR PHARMACEUTICALS INC COM in Q3 2013 and held it in 4 quarters.
  • J. Goldman & Co's ANACOR PHARMACEUTICALS INC COM position peaked at $4.02M in Q3 2015.
  • 199 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q1 2016.

Based on J. Goldman & Co's 13F filing for Q1 2016, filed 16 May 2016.